Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models

Justin K. Mikell, Yuni K. Dewaraja, Dawn Owen

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Transarterial radioembolization (TARE) with Yttrium-90 (90Y) microspheres is a liver-directed therapy for primary and metastatic disease. This manuscript provides a review of the clinical literature on TARE indications and efficacy with overviews of patient-selection and toxicity. Current dosimetry models used in practice are safe, relatively simple, and easy for clinicians to use. Planning currently relies on the imperfect surrogate, 99mTc macroaggregated albumin. Post-therapy quantitative imaging (90Y SPECT/CT or 90Y PET/CT) of microspheres can be used to calculate the macroscopic in vivo absorbed dose distribution. Similar to the evolution of other brachytherapy dose calculations, TARE is moving toward more patient-specific dosimetry that includes calculating and reporting nonuniform dose distributions throughout tumors and normal uninvolved liver.

Original languageEnglish
Pages (from-to)68-76
Number of pages9
JournalSeminars in Radiation Oncology
Volume30
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Dive into the research topics of 'Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models'. Together they form a unique fingerprint.

Cite this